	US 12,291,559 B2
	Compositions and methods for treating cancer
David DiLillo, Tarrytown, NY (US); and Thomas Craig Meagher, Tarrytown, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Oct. 20, 2023, as Appl. No. 18/382,284.
Application 18/382,284 is a continuation of application No. 17/307,235, filed on May 4, 2021, granted, now 11,826,386.
Claims priority of provisional application 63/020,177, filed on May 5, 2020.
Prior Publication US 2024/0165157 A1, May 23, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/725 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 14/7051 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4245 (2025.01); A61K 40/4268 (2025.01); A61K 40/4269 (2025.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C12N 5/0638 (2013.01); A61K 38/00 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/57 (2023.05); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01)]

15 Claims

1. A method of treating a tumor in a subject, the method comprising conjointly administering to the subject a first CAR polypeptide and a second CAR polypeptide, wherein the first CAR polypeptide comprises:

a) at least one intracytoplasmic/costimulatory region comprising a cluster of differentiation 28 zeta (CD28/ζ) domain,

b) at least one intracytoplasmic signaling region comprising a cluster of differentiation 3 zeta (CD3/ζ) domain, and

c) an antigen binding domain comprising:

(i) a light chain comprising SEQ ID NO:17 and a heavy chain comprising SEQ ID NO: 21;

(ii) a light chain comprising SEQ ID NO:18 and a heavy chain comprising SEQ ID NO: 22;

(iii) a light chain comprising SEQ ID NO:19 and a heavy chain comprising SEQ ID NO: 23;

(iv) a light chain comprising SEQ ID NO:31 and a heavy chain comprising SEQ ID NO: 32;

(v) a light chain comprising SEQ ID NO:37 and a heavy chain comprising SEQ ID NO: 38, and the second CAR polypeptide comprises:

a) a 4-1BB domain in the costimulatory region of the CAR polypeptide,

b) at least one intracytoplasmic signaling region comprising a cluster of differentiation 3 zeta (CD3/ζ) domain, and

c) an extracellular antigen binding domain comprising:

(i) a light chain comprising SEQ ID NO:17 and a heavy chain comprising SEQ ID NO: 21;

(ii) a light chain comprising SEQ ID NO:18 and a heavy chain comprising SEQ ID NO: 22;

(iii) a light chain comprising SEQ ID NO:19 and a heavy chain comprising SEQ ID NO: 23;

(iv) a light chain comprising SEQ ID NO:31 and a heavy chain comprising SEQ ID NO: 32;

(v) a light chain comprising SEQ ID NO:37 and a heavy chain comprising SEQ ID NO: 38.